The EPA is a proud partner of PsyPal, an EU-funded trial working to fill an important care gap for individuals with palliative care needs. In four European countries, we’re investigating whether psilocybin therapy can support the management of depressive symptoms…
The INSERM and CNRS Programme et Équipement Prioritaire de Recherche en Psychiatrie de Précision (PEPR PROPSY) is coordinating a Policy Initiative on Precision Psychiatry, which was featured at the European Parliament on 14 October 2026. The EPA has endorsed the…
The EPA was delighted to attend the 39th ECNP Congress in Munich from 11-13 October 2026, an excellent opportunity to meet and exchange with colleagues and partners around the latest in science and treatment of brain disorders The EPA held…
The European Medicines Agency (EMA) is establishing a pool of patient, consumer, and healthcare professional experts for the period 2024-2029. Eligible experts can be remunerated for their contributions to EMA activities and may be considered for participation in a wider range…
PsyPal, the first consortium to receive an EU clinical research grant for the study of psychedelic therapy, has published a comprehensive guidance paper to inform stakeholders across research, clinical practice, regulation, policy, advocacy, and industry. The paper outlines key considerations…
The 2026 edition is co-developed by Ambassadors of the European Psychiatric Association (EPA) and European Society of Cardiology (ESC). The survey for mental health and cardiovascular health specialists was launched at the EPA-ESC Joint Symposium in Prague on Sunday, 29…
The EPA invites clinicians to take part in the TRUSTING Survey for Evaluating Risk of Relapse, launched today, Monday, 9 February. Clinicians practising in English, Czech, Dutch, French, German, or Turkish are kindly encouraged to answer this survey aiming to…
Prof. Andrea Fiorillo, EPA President, and Prof. Celso Arango, EPA President Elect presented the latest edition of the Headway – Mental Health Index 5.0 on “Care, Cohesion, and Growth: Advancing Mental Health through the Wellbeing Economy” at the European Parliament…
Fantastic news! PsyPal has reached a major milestone with the inclusion of its first patient in the multi-site clinical trial investigating psilocybin therapy for psychological and existential distress in people with progressive, life-limiting illnesses. The EPA is proud to be…
The EPA is pleased to share the Perspective on a Mentally Healthier 2035, a joint initiative of MIND, the Dutch Association of Mental Health and Addiction Care (de Nederlandse GGZ), the Netherlands Institute of Psychologists (NIP) and the Netherlands…